CAMBRYN BIOLOGICS ANNOUNCES NEW PRODUCT DEVELOPMENT

SARASOTA, Florida –January 31, 2016, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company has initiated its internal research and development of plasma derived therapeutic products.

The initial two proteins are FibriComp™ a Fibrinogen Concentrate and a ThrombiPlex™ a Prothrombin Concentrates; additional proteins to follow are an Intravenous Immunoglobin (IVIG) and Alpha 1 Protease Inhibitor (AIPI),  The protein development is based upon Cambyrn’s unique “salting out” process using “potassium acetate” in lieu of a alcohol used in Cohn fractionation.  Salt based extraction provides significant benefits in terms of protein characterization and yield.  

The first two proteins, FibriComp™ and ThrombiPlex™ are aimed at congenital deficiencies, meaning individuals born lacking these proteins for proper coagulation.   Cambryn projects to complete the development and file an Investigative New Drug (IND) with the regulatory agencies in the US and Europe in 2017. 

About Cambryn

Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies, advanced wound healing and biosurgical hemostats. The Company specializes in the extraction and purification of human plasma proteins. Cambryn operates a 50,000 square foot state-of-the-art cGMP facility, which incorporates cleanrooms and laboratories.

For additional information contact:
Cambryn Biologics LLC
Mark P. Famiglio
Chief Executive Officer
600 Tallevast Rd – Suite 201
Sarasota, Florida USA 34243
Office: 941-355-7400
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.cambrynbiologics.com

Cambryn Biologics LLC

Cambryn Biologics LLC is a Delaware corporation having its principal facility and offices in Sarasota, Florida. Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies.

logo small

State-of-the-Art Manufacturing Facility

Our facility consists of 50,000 square feet, located adjacent to the Sarasota/Bradenton International Airport, Sarasota, Florida, USA. Cambryn Biologics operates a state-of-the-art manufacturing facility.

Contact Details

Address: 600 Tallevast Rd.
Suite 201 Sarasota, FL 34243

Phone: (941) 355-7400

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.